Chloé-Agathe Azencott

Has grant

Professor

Mines ParisTech
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Methods for discovering SNP Combinations Associated with a PHEnotype, from genome-wide data – SCAPHE

Open Date: 2018-12-21

Close Date: 2021-12-20

Grant: Close

Genome-Wide Statistical Studies of Genetic Interactions

Open Date: 2011-01-01

Close Date: 2013-03-01

Grant: Close

Machine Learning Frontiers in Precision Medicine

Open Date:

Close Date:

Grant: Close

Paris Artificial Intelligence Research Institute

Open Date:

Close Date:

Grant: Close

Advancing genotype to phenotype Studies by considering Transposable Elements Variability and Epivariability

Open Date:

Close Date:

Articles (12)

Year:

2026

Psoriasis is a common autoimmune disease with a strong genetic component. Targeting the IL-23/IL-17 pathways for the treatment of moderate-severe psoriasis has proven successful, which makes it a good benchmark for other drug discovery approaches. Genome Wide Association Studies (GWAS) identify genetic loci associated with a phenotype (e.g. disease). However, using identified loci to understand the disease mechanisms remains challenging. In response, gene networks methods that consider gene-gene relationships have been developed. In a previous study, we showed that the combination of network methods improved the power, reproducibility, and interpretability of those approaches on a small cohort of breast cancer patients. The goal of the present study is to benchmark the performance of the same combination of network methods on a psoriasis cohort from the UK biobank (with a particular interest on the IL-23/IL-17 pathways). By applying this method, we identified well known psoriasis genes, demonstrating the viability of our approach. Our method further identified a small set of genes of the MRPL family robustly associated with psoriasis, demonstrating that this approach can provide insights into the potential disease mechanisms. Our study also shows that our method is applicable to large-scale biobank data to produce novel findings, even in well-studied diseases with strong genetic signal.

Year:

2025

Advances in sequencing technologies have enabled the generation of large amounts of data, offering new possibilities to identify relationships between biological units ( e.g . genes) and phenotypic traits ( e.g . disease outcomes). Yet, identifying these associations using variable selection methods remains challenging due to the high dimension ( p ≫ n ) and the correlation structure of the data. To address these challenges, we study the applicability of the knockoff (KO) procedure. Introduced by Barber and Candès in 2015, the KO variable selection procedure has shown promising results on real biological data, such as Genome Wide Association Studies. This method seeks to identify the truly important predictors by overcoming the correlation structure between variables while controlling the false discovery rate. Here, we study the applicability of the KO procedure on transcriptomic data in a classification setting. We conduct an extensive simulation study using real transcriptomic data to evaluate the performance of the KO framework in the context of high-dimensional classification. We find that the KO framework outperforms widely used variable selection models, and that using KO aggregation to mitigate the effect of KO stochasticity improves stability while maintaining the same power. Finally applied to three real transcriptomic datasets, the KO framework made very few discoveries, highlighting its conservative nature and suggesting that other methods may substantially overestimate the number of relevant features.

Year:

2025

Table S1. Targeted bisulfite sequencing primers Table S2. Target copies and CpG sites relative to the number of sequencing reads Table S3. Statistical results of global methylation differences between healthy samples and cancer subgroups using Mann–Whitney U test Table S4. List of plasma samples. Sample IDs were not known to anyone outside the research group Table S5. Statistical results of proportion differences between healthy samples and cancer subgroups for the 372 haplotypes using Mann–Whitney U test Table S6. List of paired plasma and tissues samples and their spearman correlation for various features Table S7. Breast cancer subtype composition of M0 and M+ subgroups in C1 and C2 Table S8. Mutation screening of ovarian cancer samples from the discovery cohort Table S9. Statistical results of proportion differences between healthy samples from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S10. Statistical results of global methylation differences between healthy samples and cancer subgroups from C1 and C2 using Mann–Whitney U test Table S11. Statistical results of proportion differences between healthy samples and cancer subgroups from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S12. Statistical results of global methylation differences between original data and age-adjusted data using Mann–Whitney U test Table S13. Statistical results of global methylation differences between cancer stages using Mann–Whitney U test Table S14. Statistical results of global methylation differences between primary and metastatic tissues using Mann–Whitney U test Table S15. Statistical results of Genome-wide z-score differences between healthy samples and cancer subgroups using Mann–Whitney U test Tables S16-S22. Cancer prediction and sample labelling with the 2-step classification integrating CNA analysis - healthy vs each type of model

Year:

2025

Purpose: The detection of ctDNA, which allows noninvasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. Experimental Design: We implemented a new, highly sensitive strategy to detect bp resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of long interspersed nuclear element-1 retrotransposons as a noninvasive multicancer detection biomarker. The Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA method targets 30 to 40,000 young long interspersed nuclear element-1 retrotransposons scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline. Results: Resulting machine learning–based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from six types of cancers (colorectal, breast, lung, ovarian, and gastric cancers and uveal melanoma, including localized stages) in two independent cohorts (AUC = 88%–100%, N = 747). The Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA method can also be used to perform copy number alteration analysis that improves cancer detection. Conclusions: This should lead to the development of more efficient noninvasive diagnostic tests adapted to all patients with cancer, based on the universality of these factors. See related commentary by Szymanski et al., p. 1179

Year:

2025

Table S1. Targeted bisulfite sequencing primers Table S2. Target copies and CpG sites relative to the number of sequencing reads Table S3. Statistical results of global methylation differences between healthy samples and cancer subgroups using Mann–Whitney U test Table S4. List of plasma samples. Sample IDs were not known to anyone outside the research group Table S5. Statistical results of proportion differences between healthy samples and cancer subgroups for the 372 haplotypes using Mann–Whitney U test Table S6. List of paired plasma and tissues samples and their spearman correlation for various features Table S7. Breast cancer subtype composition of M0 and M+ subgroups in C1 and C2 Table S8. Mutation screening of ovarian cancer samples from the discovery cohort Table S9. Statistical results of proportion differences between healthy samples from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S10. Statistical results of global methylation differences between healthy samples and cancer subgroups from C1 and C2 using Mann–Whitney U test Table S11. Statistical results of proportion differences between healthy samples and cancer subgroups from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S12. Statistical results of global methylation differences between original data and age-adjusted data using Mann–Whitney U test Table S13. Statistical results of global methylation differences between cancer stages using Mann–Whitney U test Table S14. Statistical results of global methylation differences between primary and metastatic tissues using Mann–Whitney U test Table S15. Statistical results of Genome-wide z-score differences between healthy samples and cancer subgroups using Mann–Whitney U test Tables S16-S22. Cancer prediction and sample labelling with the 2-step classification integrating CNA analysis - healthy vs each type of model

Year:

2025

Year:

2024

Purpose: The detection of ctDNA, which allows noninvasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. Experimental Design: We implemented a new, highly sensitive strategy to detect bp resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of long interspersed nuclear element-1 retrotransposons as a noninvasive multicancer detection biomarker. The Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA method targets 30 to 40,000 young long interspersed nuclear element-1 retrotransposons scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline. Results: Resulting machine learning–based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from six types of cancers (colorectal, breast, lung, ovarian, and gastric cancers and uveal melanoma, including localized stages) in two independent cohorts (AUC = 88%–100%, N = 747). The Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA method can also be used to perform copy number alteration analysis that improves cancer detection. Conclusions: This should lead to the development of more efficient noninvasive diagnostic tests adapted to all patients with cancer, based on the universality of these factors. See related commentary by Szymanski et al., p. 1179

Year:

2024

Drug-target interactions (DTIs) prediction algorithms are used are various stages of the drug discovery process. In this context, specific problems such as de-orphanization of a new therapeutic target, or target identification of a drug candidate arising from phenotypic screens require large-scale predictions across the protein and molecule spaces. DTI prediction heavily relies on supervised learning algorithms that use known DTIs to learn associations between molecule and protein features, allowing for the prediction of new interactions based on learned patterns. The algorithms must be broadly applicable to enable reliable predictions, even in regions of the protein or molecule spaces where data may be scarce. In this paper, we address two key challenges to fulfil these goals: building large, high-quality training datasets and designing prediction methods that can scale, in order to be trained on such large datasets. First, we introduce LCIdb, a curated, large-sized dataset of DTIs, offering extensive coverage of both the molecule and druggable protein spaces. Notably, LCIdb contains a much higher number of molecules than publicly available benchmarks, expanding coverage of the molecule space. Second, we propose Komet (Kronecker Optimized METhod), a DTI prediction pipeline designed for scalability without compromising performance. Komet leverages a three-step framework, incorporating efficient computation choices tailored for large datasets and involving the Nyström approximation. Specifically, Komet employs a Kronecker interaction module for (molecule, protein) pairs, which efficiently captures determinants in DTIs, and whose structure allows for reduced computational complexity and quasi-Newton optimization, ensuring that the model can handle large training sets, without compromising on performance. Our method is implemented in open-source software, leveraging GPU parallel computation for efficiency. We demonstrate the interest of our pipeline on various datasets, showing that Komet displays superior scalability and prediction performance compared to state-of-the-art deep learning approaches. Additionally, we illustrate the generalization properties of Komet by showing its performance on an external dataset, and on the publicly available ℒℌ benchmark designed for scaffold hopping problems. Komet is available open source at https://komet.readthedocs.io and all datasets, including LCIdb, can be found at https://zenodo.org/records/10731712 .

Year:

2024

Purpose The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. Experimental Design We implemented a new highly sensitive strategy to detect base-pair resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of LINE-1 retrotransposons as a non-invasive multi-cancer detection biomarker. The DIAMOND (Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA) method targets 30-40,000 young L1 scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline. Results Resulting machine learning-based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from 6 types of cancers (colorectal, breast, lung, ovarian, gastric cancers and uveal melanoma including localized stages) in two independent cohorts (AUC = 88% to 100%, N = 747). DIAMOND can also be used to perform copy number alterations (CNA) analysis which improves cancer detection. Conclusions This should lead to the development of more efficient non-invasive diagnostic tests adapted to all cancer patients, based on the universality of these factors. Statement of significance The DIAMOND assay is a new highly sensitive strategy to detect base-pair resolution methylation patterns of LINE-1 retrotransposons (L1) from plasma DNA. It targets 30-40,000 young L1 scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline. This provided high coverage data using affordable sequencing depth, which is instrumental to achieve high sensitivity and work with minute amounts of cell-free DNA. Resulting machine learning-based classifiers showed powerful discrimination between healthy and tumor plasmas from 6 types of cancers (colorectal, breast, lung, ovarian, gastric cancers and uveal melanoma including localized stages) in two independent cohorts (AUC = 88% to 100%, N = 747). DIAMOND data can also be used to perform copy number alterations (CNA) analysis which improves cancer detection.

Year:

2024

Year:

2023

Year:

2023

Collaborators (11)

Charlotte Proudhon

INSERM scientist, Group leader - Team Circulating EpiMarkers

-

FRANCE
View details

Olivier Lantz

Institut Curie

FRANCE
View details

Makoto Yamada

Okinawa Institute of Science and Technology Graduate University

JAPAN
View details

Florian Massip

-

FRANCE
View details

Ivan Bieche

Université Paris Cité

FRANCE
View details

Veronique STOVEN

Professor

MINES Paris - PSL

FRANCE
View details

Christophe Le Tourneau

Head of Early Phase Clinical Trials

Institut Curie

FRANCE
View details

Julio Molineros

Janssen Pharmaceuticals

UNITED STATES
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Jean-Yves Pierga

Head of Department

Institut Curie

FRANCE
View details

Maud Kamal

Institut Gustave Roussy

FRANCE
View details